Sarcoma Great Debate: Neoadjuvant Chemotherapy Should be Standard Practice for High-Risk Retroperitoneal Sarcomas

Moderator(s)

• 

  Valerie Grignol, MD

  Associate Professor of Surgery
  The Ohio State University
  Columbus, Ohio, United States

  Disclosure(s): No financial relationships to disclose

Patients with retroperitoneal dedifferentiated liposarcoma and leiomyosarcoma are at high risk for developing hematogenous metastatic disease. Although many institutions utilize neoadjuvant chemotherapy, the absolute benefit is not clear. As there is currently no completed randomized prospective study addressing neoadjuvant chemotherapy, the debators will vigorously discuss the pros and cons of this approach.

Presentations:

• 4:00pm – 4:15pm ET

  Pro: Neoadjuvant Chemotherapy Should be Standard Practice for High-Risk Retroperitoneal Sarcomas
  

  Debater - Pro: Kenneth Cardona, MD – Winship Cancer Institute, Emory University
• 4:15pm – 4:30pm ET

  Con: Neoadjuvant Chemotherapy Should be Standard Practice for High-Risk Retroperitoneal Sarcomas
  

  Debater - Con: Rebecca A. Gladdy, MD, PhD (she/her/hers) – Sinai Health System, Princess Margaret Cancer Centre
• 4:30pm – 4:45pm ET

  Questions & Discussion